Create Account
Sign In
Dark
chart
exchange
Terminal
Screener
Stocks
Crypto
Forex
Watchlists
Trends

AGLE
Aeglea BioTherapeutics Inc
stock NASDAQ

At Close
2/3/2023 3:59:55 PM EST
0.5040USD+2.857%(+0.0140)232,347
0.4800Bid   0.5200Ask   0.0400Spread IEX
Pre-market
2/3/2023 9:25:30 AM EST
0.5145USD+5.000%(+0.0245)0
After-hours
1/26/2023 4:00:30 PM EST
0.4930USD0.000%(0.0000)0
OverviewOption ChainHistoricalExchange VolumeShort VolumeBorrow FeeFailure to DeliverTrendsNewsMore
open chart   
open chart   
Market Cap
31.002M
Headquarters
TX, USA
Industry
Biotechnology
Related
OMERXLV
AGLE Stats
Avg. Vol. 10 Day
190,723
Avg. Vol. 30 Day
394,497
Employees
69
Market Cap
31,001,583
Shares Out.
61,511,078
Float
32,482,155
On/Off Exchange
49%/51%
6 Month Beta
0.02
1 Year Beta
0.51
2 Year Beta
0.42
3 Year Beta
1.12
52 Week Low
0.34
52 Week High
4.50
SMA50
0.46
SMA200
0.60
1 Week
+4.54%
1 Month
-2.14%
3 Month
-54.60%
6 Month
+19.91%
1 Year
-88.20%
2 Year
-93.37%
5 Year
-91.96%
Jan 25, 2022
08:03AM EST  Aeglea BioTherapeutics Announces Upcoming KOL and Patient Caregiver Webinar on   PR Newswire
Jan 5, 2022
07:02AM EST  Aeglea BioTherapeutics to Participate in Two Investor Conferences in January   PR Newswire
Dec 14, 2021
05:03AM EST  Aeglea BioTherapeutics CEO Anthony Quinn Reported 53,634 Shares @ Avg Price of $3.71/Share in Form 4 Filing on Monday   Benzinga
Dec 6, 2021
02:31PM EST  Mid-Afternoon Market Update: Dow Jumps 700 Points; Del Taco Restaurants Shares Spike Higher   Benzinga
12:30PM EST  Mid-Day Market Update: Crude Oil Rises 3%; Aeglea BioTherapeutics Shares Plunge   Benzinga
More News
Profile
Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare and devastating metabolic diseases with limited treatment options. Aeglea's lead product candidate, pegzilarginase, is in a pivotal Phase 3 trial for the treatment of Arginase 1 Deficiency and has received both Rare Pediatric Disease and Breakthrough Therapy Designation. In the second quarter of 2020, the Company initiated a Phase 1/2 clinical trial of AGLE-177 for the treatment of Homocystinuria. AGLE-177 has also been granted Rare Pediatric Disease Designation. Aeglea has an active discovery platform focused on engineering small changes in human enzymes to have a big impact on the lives of patients and their families.

AGLE Stock Summary

Aeglea BioTherapeutics Inc (NASDAQ:AGLE) stock price today is $0.5040, and today's volume is 232,347. AGLE is up 2.857% today. The 30 day average volume is 394,497. AGLE market cap is 31.002M with 61,511,078 shares outstanding.



Share
About
Symbol List

Pricing
Disclaimer

ChartExchange on Twitter
ChartExchange on Reddit
© 2020 - 2023 ChartExchange LLC